The present invention relates to a new delivery system for fat-soluble vitamins.

The present invention relates to a new delivery system for fat-soluble vitamins.

The present invention discloses a composition and method of use for the general improvement of hypertension, high cholesterol, and cardiovascular health. The novel composition is comprised of thiamin (vitamin B1), vitamin B2 (as riboflavin-5′-phosphate), niacin (vitamin B3, as niacinamide), vitamin B6 (as pyridoxine hydrochloride), folic acid, vitamin C, vitamin D, calcium (as calcium carbonate), magnesium (as magnesium taurate), aged garlic extract, olive leaf extract (as 20% oleuropein), coenzyme Q10 (as ubiquinol), L-Arginine (as hydrochloride), L-Citrulline (as malate), and lycopene.

The present invention discloses a composition and method of use for the general improvement of hypertension, high cholesterol, and cardiovascular health. The novel composition is comprised of thiamin (vitamin B1), vitamin B2 (as riboflavin-5′-phosphate), niacin (vitamin B3, as niacinamide), vitamin B6 (as pyridoxine hydrochloride), folic acid, vitamin C, vitamin D, calcium (as calcium carbonate), magnesium (as magnesium taurate), aged garlic extract, olive leaf extract (as 20% oleuropein), coenzyme Q10 (as ubiquinol), L-Arginine (as hydrochloride), L-Citrulline (as malate), and lycopene.

Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).

Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).

Disclosed are controlled release particles including: (a) a core including at least one vitamin which is oil-soluble or oil-dispersible; and (b) a wall at least partially surrounding the core, wherein the controlled release particles are produced by reacting (i) a first composition including a hydrophobic oil, the at least one vitamin, an anti-oxidant and a wax with (ii) a second composition including a water soluble emulsifier, a corn protein and a solvent to form an intermediate product, which is mixed with (iii) a third composition including a cellulosic polymer in water, and dehydrated to provide the controlled release particles. A method for preparing the particles and compositions containing the particles are also disclosed.

Disclosed are controlled release particles including: (a) a core including at least one vitamin which is oil-soluble or oil-dispersible; and (b) a wall at least partially surrounding the core, wherein the controlled release particles are produced by reacting (i) a first composition including a hydrophobic oil, the at least one vitamin, an anti-oxidant and a wax with (ii) a second composition including a water soluble emulsifier, a corn protein and a solvent to form an intermediate product, which is mixed with (iii) a third composition including a cellulosic polymer in water, and dehydrated to provide the controlled release particles. A method for preparing the particles and compositions containing the particles are also disclosed.

The invention relates to an anti-hypercholesterolemia composition and a method of manufacturing the composition. Accordingly, the present invention discloses the composition to lower the cholesterol formation and a method of manufacturing the same. The anti-hypercholesterolemia composition comprises Basella alba leaf extract in the range of 30 to 70 wt %, red yeast rice extract in the range of 5 to 50 wt %, squalene extract in the range of 1 to 30 wt %, Cordyceps extract in the range of 10 to 70 wt % and at least one nutraceutically or pharmaceutically acceptable excipient in the range of 0.01 to 50 wt %.

The invention relates to an anti-hypercholesterolemia composition and a method of manufacturing the composition. Accordingly, the present invention discloses the composition to lower the cholesterol formation and a method of manufacturing the same. The anti-hypercholesterolemia composition comprises Basella alba leaf extract in the range of 30 to 70 wt %, red yeast rice extract in the range of 5 to 50 wt %, squalene extract in the range of 1 to 30 wt %, Cordyceps extract in the range of 10 to 70 wt % and at least one nutraceutically or pharmaceutically acceptable excipient in the range of 0.01 to 50 wt %.